Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 17/20 | 0.56 |
| ▸ | FLT1 | P17948 | 6/20 | 0.56 |
| ▸ | KIT | P10721 | 4/20 | 0.56 |
| ▸ | BRAF | P15056 | 2/20 | 0.56 |
| ▸ | RET | P07949 | 2/20 | 0.55 |
| ▸ | MAP3K20 | Q9NYL2 | 2/20 | 0.55 |
| ▸ | RIPK3 | Q9Y572 | 2/20 | 0.55 |
| ▸ | ABL1 | P00519 | 3/20 | 0.53 |
| ▸ | CSF1R | P07333 | 3/20 | 0.53 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.53 |
| ▸ | FLT4 | P35916 | 3/20 | 0.53 |
| ▸ | EGFR | P00533 | 2/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.48 |
| ▸ | IGF1R | P08069 | 1/20 | 0.48 |
| ▸ | TEK | Q02763 | 1/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
| ▸ | CIT | O14578 | 1/20 | 0.45 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.45 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.45 |
| ▸ | STK10 | O94804 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6014635 | 0.88 | KDR (0.52) | KDRFLT1KITBRAFRET | |
| SCHEMBL6014554 | 0.87 | RET (0.72) | KDRFLT1KITBRAFRET | |
| SCHEMBL6014513 | 0.84 | RET (0.73) | KDRFLT1KITBRAFRET | |
| SCHEMBL6014673 | 0.82 | RET (0.76) | KDRFLT1KITBRAFRET | |
| SCHEMBL6014604 | 0.82 | RET (0.70) | KDRFLT1KITBRAFRET | |
| SCHEMBL6014721 | 0.81 | RET (0.75) | KDRFLT1KITBRAFRET | |
| SCHEMBL4977683 | 0.81 | KDR (0.71) | KDRFLT1KITBRAFABL1 | |
| SCHEMBL4979677 | 0.79 | KDR (0.71) | KDRFLT1KITBRAFABL1 | |
| SCHEMBL3005186 | 0.79 | KDR (0.71) | KDRFLT1KITBRAFABL1 | |
| SCHEMBL30846489 | 0.79 | KDR (0.71) | KDRFLT1KITBRAFABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1633712-B1 | SIX MEMBERED AMINO-AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS | CHEN GUOQING PAUL (US) | 2014-06-25 | — | — | EP | claimed |
| US-7129252-B2 | Six membered amino-amide derivatives an angiogenisis inhibitors | HLB CO., LTD. (KR) | 2006-10-31 | — | — | US | claimed |
| EP-1633712-A2 | SIX MEMBERED AMINO-AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS | Chen, Guoqing Paul (US) | 2006-03-15 | — | — | EP | claimed |
| WO-2005000232-A2 | SIX MEMBERED AMINO-AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS | CHEN GUOQING PAUL (US) | 2005-01-06 | — | — | WO | claimed |
| US-20040259916-A1 | Six membered amino-amide derivatives an angiogenisis inhibitors | HLB CO., LTD. (KR) | 2004-12-23 | — | — | US | claimed |
| EP-1633712-B1 | SIX MEMBERED AMINO-AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS | CHEN GUOQING PAUL (US) | 2014-06-25 | — | — | EP | disclosed |
| US-7129252-B2 | Six membered amino-amide derivatives an angiogenisis inhibitors | HLB CO., LTD. (KR) | 2006-10-31 | — | — | US | disclosed |
| EP-1633712-A2 | SIX MEMBERED AMINO-AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS | Chen, Guoqing Paul (US) | 2006-03-15 | — | — | EP | disclosed |
| WO-2005000232-A2 | SIX MEMBERED AMINO-AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS | CHEN GUOQING PAUL (US) | 2005-01-06 | — | — | WO | disclosed |
| US-20040259916-A1 | Six membered amino-amide derivatives an angiogenisis inhibitors | HLB CO., LTD. (KR) | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259916-A1 | Six membered amino-amide derivatives an angiogenisis inhibitors | TEK, FLT1, VEGFA | KDR 7/4885FLT1 2/4885KIT 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.